Health-Care Stocks Save the S&P 500 From Stumbling as the Dow Slumbers

Many of the S&P's best performers are drugmakers or pharmacy chains, and that might be the difference between its narrow gain and the Dow's mediocrity today.

May 5, 2014 at 12:20PM

All three of the major American stock indices have recovered quickly from fairly large opening-bell dips to trade just above breakeven at lunchtime on Monday. Most of the Dow Jones Industrial Average's (DJINDICES:^DJI) 30 components are trading slightly lower -- only eight had produced gains of greater than 0.25% shortly before noon EDT -- but roughly 225 of the broader S&P 500's (SNPINDEX:^GSPC) components are in positive territory.

Longview

Last week's divergent economic news of disappointing first-quarter gross domestic product growth but a solid uptick in employee hires left many investors unsure of what to do, and the start of this week hasn't provided much certainty yet. Weakness in China's closely watched manufacturing index and the fear of further military escalation between Russia and Ukraine have thus far been offset by a strong Institute for Supply Management report on nonmanufacturing productivity.

That gauge of service-sector production hit a new orders number of 58.2 (anything below 50 signals recession) in March, which is its strongest level this year and also slightly higher than September's 58.1 mark. The overall PMI was 55.2. It appears that the Dow's industrially focused stocks are reaping most of the rewards of the service-sector report, as Boeing, DuPont, and energy giants ExxonMobil and Chevron are four of the Dow's strongest today.

Only Disney (NYSE:DIS) is leading a charge for the Dow's numerous service-focused stocks, as its 0.9% rise puts it neck and neck with ExxonMobil's for the second-best gain of all 30 components -- only Boeing has gained over 1% so far today. Topeka Capital today upgraded the House of Mouse's shares to buy status, with a new $91 price target. The new price target gives Disney shares about 12% of further upside, which is a pretty modest expectation for a stock that has already gained over 25% in the past year. Boeing, for its part, continues to ride the positive sentiment generated by a solid sales report released on Friday. Fool aerospace and defense specialist Rich Smith has all the juicy details: in short, the airplane maker has collected 13% more orders this year than it did at the same point in 2013.

Pillbottle

Source: Darren Hester via DeviantArt.

The Dow might be languishing, but the S&P has a very narrow edge on its smaller peer today thanks to a broad-based but not particularly powerful gain in many larger health-care stocks. The S&P's biggest gainer, shortly before noon, was Biogen Idec, but other biotech heavyweights including Gilead Sciences (NASDAQ:GILD), Alexion Pharmaceuticals, and Vertex Pharmaceuticals were among the index's leaders today. Both CVS Caremark (NYSE:CVS) and Walgreen were also among the S&P's 20 best-performing stocks so far.

Of these gainers, all but Alexion have developed a hepatitis treatment, and Gilead's market-destroying sales of apparent blockbuster (and wallet-buster) hepatitis C treatment Sovaldi has given many rivals reasons to be optimistic as well, provided they can also achieve a measure of success with their treatments. CVS reported first-quarter earnings on Friday evening, and it is clearly growing strongly for such a large and well-established retail company. For Biogen, Gilead, and pharmacy chains CVS and Walgreen, it seems likely that Obamacare's evident success in signing up more people for health insurance than it had promised has created positive momentum beyond what investors might have hoped for otherwise. Last Wednesday's GDP report supports this idea, as unprecedented growth in the health-care sector was really the only thing standing between the American economy and a mild recession in the first quarter.

Invest in the next wave of health-care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Alex Planes has no position in any stocks mentioned. The Motley Fool recommends Chevron, CVS Caremark, Gilead Sciences, Vertex Pharmaceuticals, and Walt Disney. The Motley Fool owns shares of Gilead Sciences and Walt Disney. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers